Skip to main content

Animations

MJFF Publications

2341 - 2350 of 7939 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • RESTRICTED
    Title: Amantadine in the treatment of Parkinson's disease and other movement disorders
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0
    Best OA location URL:
    Citation Count: 73
  • RESTRICTED
    Title: Autophagy and the hallmarks of aging
    Journal Name: Ageing Research Reviews
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.arr.2021.101468
    Citation Count: 115
  • RESTRICTED
    Title: Corrigendum to “Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys” [EBioMedicine 2020; 59:102944]
    Journal Name: eBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2021.103731
    Citation Count: 0
  • OPEN
    Title: Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-021-00491-y
    Citation Count: 34
  • RESTRICTED
    Title: Disease modifying therapies for Parkinson's disease: Novel targets
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108839
    Best OA location URL:
    Citation Count: 4
  • OPEN
    Title: Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice
    Journal Name: Cell Reports Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.xcrm.2021.100455
    Citation Count: 22
  • RESTRICTED
    Title: LRRK2 signaling in neurodegeneration: two decades of progress
    Journal Name: Essays in Biochemistry
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1042/ebc20210013
    Best OA location URL:
    Citation Count: 10
  • RESTRICTED
    Title: Neuropathological evidence of body-first vs. brain-first Lewy body disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2021.105557
    Citation Count: 87
  • OPEN
    Title: Programmed autophagy prevents excess organelle baggage during neurogenesis
    Journal Name: Molecular Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa, publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.molcel.2021.11.034
    Citation Count: 0
  • OPEN
    Title: Progression of Self-Perceived Speech and Swallowing Impairment in Early Stage Parkinson's Disease: Longitudinal Analysis of the Unified Parkinson's Disease Rating Scale
    Journal Name: Journal of Speech, Language, and Hearing Research
    Publisher: American Speech Language Hearing Association
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1044/2021_jslhr-21-00216
    Citation Count: 7
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.